This week’s podcast is sponsored by Nipro.

This week, our conversations are with Jesus Garcia, Nipro Product Manager Water Treatment, on Nipro ’s recently-launched product LiniXia, a reverse osmosis (RO) system that ensures safe and pure water for every dialysis session, and on the future of biologics manufacturing with cell-free protein synthesis with LenioBio CEO André Goerke.

Interview times:

05:16 Nipro

15:52 LenioBio

NIPRO

Nipro Medical Europe is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 40.000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries.

Nipro Medical Europe is a global market leader offering a comprehensive portfolio of medical disposables and machines across six divisions: Renal, Hospital Products, Diabetes, Cardiopulmonary, Enzymes, and In Vitro Diagnostics.

With a worldwide footprint of manufacturing sites, sales offices, and distribution centres, NIPRO Medical Europe services the EMEA region. From hospitals to home care, Nipro provides products that improve the lives of patients and meet the needs of healthcare professionals and procurement managers alike.

Nipro recently launched LiniXia, its new Reverse Osmosis (RO) system that reliably ensures safe and pure water for every dialysis session.

With LiniXia, Nipro has added an entire range of water treatment solutions to its renal care portfolio, combining innovative RO technology with user-friendly controls, detailed logs, and remote supervision capabilities, all while ensuring up to 90% yield of high quality ultra-pure water.

Visit http://www.nipro-group.com/renal-care for more information.

Our conversation is with Jesus Garcia, Nipro Product Manager Water Treatment.

LenioBio

LenioBio GmbH is a life sciences biotech company dedicated to transforming protein production through its proprietary ALiCE technology.

By eliminating the limitations and bottlenecks of traditional cell-based systems, LenioBio empowers researchers to explore new frontiers in protein expression and accelerate the development of cutting-edge therapeutics and diagnostics.

ALiCE was launched earlier this year. It is the first eukaryotic cell-free expression platform specifically engineered for rapid antibody discovery and screening. By offering an end-to-end service covering DNA template generation, lead generation, purification and analysis, this new solution slashes production timelines from four weeks to as little as three days.

We had a conversation on ALiCE and the future of biologics manufacturing with cell-free protein synthesis with LenioBio CEO André Goerke.

To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

This week, we have conversations with Eduardo Bravo, CEO of Citryll, and Dermot Tierney, COO of AMPLY Discovery.

Interview times:

02:53 Citryll

21:56 AMPLY Discovery

Citryll

Citryll’s recent Series B financing of €85m at the end of last year is helping to advance its first-in-class therapy targeting neutrophil extracellular traps (NETs).

Discovered in 2004, NETs are web-like structures released by white blood cells that are now understood to be fundamental drivers of inflammation - yet they've never been successfully targeted therapeutically.

Three major strategic investors are backing this novel biological approach, suggesting potential for a new therapeutic class. Following phase 1 completion, Citryll is advancing into Phase 2a trials in both rheumatoid arthritis and hidradenitis suppurativa.

We spoke with Bravo about the implications of targeting this newly understood biological pathway and the potential market impact.

AMPLY Discovery

AMPLY Discovery is an AI company finding nature's own solutions to drug-resistant infections.

Dermot Tierney is COO of AMPLY Discovery, a Queen's University Belfast spinout that's taken a different approach to the AMR crisis. Instead of trying to design new antimicrobials from scratch, they're using AI to discover what evolution already perfected over millions of years.

The AMPLY platform connects the digital biological biome to high volume peptide, protein and RNAi extraction technology to unlock a new frontier in drug discovery.

To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

This week, our subjects are a silica nanoparticle gene delivery system in a conversation with Nigel Theobald, CEO of N4 Pharma, and a point-of-care diagnostics system for urinary tract infections developed by Welsh company Llusern Scientific. We spoke with the company's co-founder and CEO, Dr Emma Hayhurst.

Interview times:

03:00 N4 Pharma

24:45 Llusern Scientific

N4 Pharma

N4 Pharma is a UK biotech company developing a silica nanoparticle gene delivery system called Nuvec.

Nuvec is being used to enable advanced therapies for cancer and other diseases. N4 Pharma has developed a pre-clinical RNA therapeutic, N4 101, which is a patient-friendly orally delivered inflammation inhibitor for inflammatory bowel disease (IBD) using Nuvec.

N4 Pharma announced positive results from its first in vivo study, which explored the therapeutic potential of orally administered Nuvec particles loaded with siRNA alone and combined with mRNA.

We had a conversation with Nigel Theobald, CEO of N4 Pharma, about the company and its work.

Llusern Scientific

Llusern Scientific is a treatment-directing molecular diagnostics company, developing fast, accurate, and accessible tools to guide real-time clinical decision-making at the point-of-care.

Its solution, Lodestar DX, is a portable diagnostic device that delivers lab-accurate results for urinary tract infections (UTIs) in around half an hour.

As well as providing guidance on the best treatment option based on the specific microbial infection, Lodestar DX also provides a clear ‘rule-out’ decision where antibiotics are not necessary, helping to reduce antimicrobial resistance through antibiotic stewardship.

Our guest on the podcast is Llusern Scientific co-founder and CEO, Dr Emma Hayhurst.

To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com